Arrakis Therapeutics Announces $38 Million Series A Financing to Target RNA with Small-Molecule Medicines and Names Michael Gilman Chairman and CEO

WALTHAM, Mass.–(BUSINESS WIRE)–Arrakis Therapeutics, a pioneering biopharmaceutical company, has completed a $38 million Series A financing led by Canaan Partners with participation by Advent Life Sciences, Pfizer Inc., Celgene Corporation, Osage University Partners, and biotech industry leader Henri Termeer. The Read more ...

The post Arrakis Therapeutics Announces $38 Million Series A Financing to Target RNA with Small-Molecule Medicines and Names Michael Gilman Chairman and CEO appeared first on Biggies Boxers.

source http://www.biggiesboxers.com/arrakis-therapeutics-announces-38-million-series-a-financing-to-target-rna-with-small-molecule-medicines-and-names-michael-gilman-chairman-and-ceo/